Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 12, 2023Circulation

Oral anticoagulation with edoxaban or apixaban reduces the risk of stroke in patients with device-detected atrial fibrillation but increases the risk of major bleeding.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does oral anticoagulation with edoxaban or apixaban reduce the risk of stroke in patients with device-detected atrial fibrillation?

Population

Patients with device-detected atrial fibrillation in 2 large randomized trials

Comparison

Oral anticoagulation with edoxaban or apixaban

Design

Study-level meta-analysis of 2 randomized trials

Authors

WMWilliam F. McIntyreABAlexander P. BenzNBNina Becher

Discussion

Loading...

Member takes

Overview

Guides individualized anticoagulation decisions in device-detected AF by balancing stroke prevention against bleeding; extends RCT evidence via meta-analysis.

Structured PICO

Does oral anticoagulation with edoxaban or apixaban reduce the risk of stroke in patients with device-detected atrial fibrillation?

P
Population
Patients with device-detected atrial fibrillation (meta-analysis of 2 large randomized trials: NOAH-AFNET 6 and ARTESiA)
I
Intervention
Oral anticoagulation with direct oral anticoagulants (edoxaban or apixaban)
O
Outcome
Strokehard clinical

In patients with device-detected atrial fibrillation, oral anticoagulation with edoxaban or apixaban effectively reduces stroke risk at the cost of increased major bleeding.

Cite This Study

McIntyre et al. (2023) studied this question.

synapsesocial.com/papers/69d570ea75589c71d767e01dhttps://doi.org/10.1161/circulationaha.123.067512
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discrepant Outcomes of Direct Oral Anticoagulant Trials in Device-Detected Atrial Fibrillation after Stroke: Insights from NOAH-AFNET 6 and ARTESIA2026
  2. 2Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: assessing net clinical benefit2024 · 5 citations
  3. 3Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials2024 · 37 citations
  4. 4Efficacy and safety of direct oral anticoagulants in patients with device-detected atrial fibrillation with and without dose reduction criteria: a pooled analysis of ARTESiA and NOAH-AFNET 62025
  5. 5Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial2017 · 230 citations